Extensive legal experience with private and
public biotech companies, including Biogen, IVAX Corporation and
Cell Signaling Technology
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC)
(“PureTech” or the “Company”), a clinical-stage biotherapeutics
company, announced today that its Founded Entity, Vedanta
Biosciences (“Vedanta”) has appointed Simona Levi, Ph.D., J.D., as
Chief Legal Officer and Corporate Secretary. Dr. Levi brings over
25 years of United States and international legal experience with
private and public companies across the life sciences industry
focusing on complex transactions, intellectual property law and
litigation, and corporate governance.
Dr. Levi joins Vedanta from Cell Signaling Technology (CST),
Inc., where she served as the general counsel and corporate
secretary managing all legal matters including assisting with the
formation of the company’s global subsidiaries and structuring all
financial transactions. Dr. Levi spent more than 25 years working
as legal counsel for corporate and intellectual property matters in
the life sciences industry. Most notably, she was a partner at the
law firm McDermott Will & Emery, served as director of
neurology for Biogen, and was a senior IP counsel for IVAX
Corporation.
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Appoints Simona Levi as
Chief Legal Officer and Corporate Secretary
Extensive legal experience with private and
public biotech companies, including Biogen, IVAX Corporation and
Cell Signaling Technology
CAMBRIDGE, MA, October 14, 2021 – Vedanta Biosciences, a
clinical-stage company that is developing a potential new category
of oral therapies based on defined bacterial consortia, today
announced the appointment of Simona Levi, Ph.D., J.D., as Chief
Legal Officer and Corporate Secretary. Dr. Levi brings over 25
years of United States and international legal experience with
private and public companies across the life sciences industry
focusing on complex transactions, intellectual property law and
litigation, and corporate governance.
“Simona’s deep legal experience and proven track record in the
life sciences industry will be critical as we execute on our vision
to enable a new class of drugs in the microbiome field,” said
Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of
Vedanta Biosciences. “We are excited to welcome Simona to the
Vedanta team and look forward to her contributions.”
Dr. Levi joins Vedanta from Cell Signaling Technology (CST),
Inc., where she served as the general counsel and corporate
secretary managing all legal matters including assisting with the
formation of the company’s global subsidiaries and structuring all
financial transactions. Dr. Levi spent more than 25 years working
as legal counsel for corporate and intellectual property matters in
the life sciences industry. Most notably, she was a partner at the
law firm McDermott Will & Emery, served as director of
neurology for Biogen, and was a senior IP counsel for IVAX
Corporation.
Dr. Levi has a B.A. in biochemistry and economics, a Ph.D. in
biochemistry from Rutgers University and a J.D. from the University
of Pennsylvania Law School. Dr. Levi has been a member of the
Massachusetts Bar Association since 1995.
“With the recent activity and interest in the microbiome field,
it has become clear that Vedanta has shown great promise in
pioneering defined bacterial consortia as a new class of
therapeutics,” said Dr. Levi. “Vedanta has assembled a talented and
dedicated team and I am thrilled to be joining such a dynamic
company at this pivotal stage of its growth.”
About Vedanta Biosciences Vedanta Biosciences is leading
the development of a potential new category of oral therapies based
on defined consortia of bacteria isolated from the human microbiome
and grown from pure clonal cell banks. The company’s clinical-stage
pipeline includes product candidates being evaluated for the
treatment of high-risk C. difficile infection, inflammatory bowel
diseases, advanced or metastatic cancers, and food allergy. These
investigational therapies are grounded in pioneering research –
published in leading journals including Science, Nature, and Cell –
to identify beneficial bacteria that live symbiotically within the
healthy human gut, fight pathogens and induce a range of potent
immune responses. Vedanta Biosciences controls a foundational
portfolio of more than 40 patents and has built what it believes to
be the world’s biggest library of bacteria derived from the human
microbiome. Proprietary capabilities include deep expertise in
consortium design, vast datasets from human interventional studies
and cGMP-compliant manufacturing of oral live biotherapeutic
candidates containing pure, clonally derived bacterial consortia in
powdered form. Vedanta Biosciences was founded by PureTech Health
(Nasdaq: PRTC, LSE: PRTC) and a global team of scientific
co-founders who pioneered Vedanta’s modern understanding of the
cross-talk between the microbiome and the immune system.
About PureTech Health PureTech is a clinical-stage
biotherapeutics company dedicated to discovering, developing and
commercializing highly differentiated medicines for devastating
diseases, including inflammatory, fibrotic and immunological
conditions, intractable cancers, lymphatic and gastrointestinal
diseases and neurological and neuropsychological disorders, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 25
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization, as of the date of PureTech's most recently filed
Half Year Report and corresponding Form 6-K. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation statements that relate to
Vedanta’s future prospects, development plans, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks, uncertainties and other
important factors that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other
important factors described under the caption “Risk Factors” in our
Annual Report on Form 20-F for the year ended December 31, 2020
filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we
disclaim any obligation to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211014005202/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024